Table 2.
Biologics under development for psoriasis as of June 2017. Search at www.clinicaltrial.gov.
| Biologic | Type | Target | Stage of Development | www.clinicaltrial.gov |
|---|---|---|---|---|
| Guselkumab | Human Ig 1G1 monoclonal antibody | IL 2-23p19 | Approved | |
| Tildrakizumab | Humanized Ig 1G1 monoclonal antibody | IL-23p19 | Phase III |
NCT01722331 NCT01729754 |
| Risankizumab | Humanized IgG1 monoclonal antibody | IL-23p19 | Phase III |
NCT03047395 NCT02672852 NCT02684370 NCT02694523 NCT02684357 |
| Certolizumab Pegol | PEGylated Fab’ fragment of a humanized IgG1 monoclonal antibody | TNF-α | Phase III |
NCT02326298 NCT02326272 NCT02346240 |
| Bimekizumab | Humanized IgG1 monoclonal antibody | IL-17A and IL-17F | Phase II |
NCT03025542 NCT03010527 NCT02905006 |
| Neihulizumab | Humanized monoclonal antibody | CD 3162 on T-cells | Phase II |
NCT02223039 NCT01855880 |
| CJM112 | Human monoclonal antibody | IL-17A | Phase II | NCT01828086 |
| Namilumab | Human IgG1 monoclonal antibody | GM-CSF 4 | Phase II | NCT02129777 |
| Mirikizumab | Humanized monoclonal antibody | IL-23p19 | Phase II | NCT02899988 |
| TAB08 | Humanized IgG4 monoclonal antibody | CD28 on T-cells | Phase II | NCT02796053 |
| GSK2831781 | Humanized antibody dependent cell cytotoxicity enhanced monoclonal afucosylated IgG1antibody | Lymphocyte activation gene-3 | Phase I | NCT02195349 |
| T1h | Humanized IgG1 monoclonal antibody | CD6 | Phase I | NCT02649270 |
| MSB0010841 | Nanobody | IL-17A and IL-17F | Phase I | NCT02156466 |
1 Ig: Immunoglobulin. 2 IL: Interleukin. 3 CD: Cluster of Differentiation. 4 GM-CSF: Granulocyte-macrophage colony-stimulating factor.